Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 22;13(5):e0197148.
doi: 10.1371/journal.pone.0197148. eCollection 2018.

Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study

Angelika Chachaj  1 , Jerzy Wiśniewski  2 , Justyna Rybka  3 , Aleksandra Butrym  4   5 , Monika Biedroń  3 , Małgorzata Krzystek-Korpacka  2 , Mariusz Grzegorz Fleszar  2 , Maciej Karczewski  6 , Tomasz Wróbel  3 , Grzegorz Mazur  5 , Andrzej Gamian  2   7 , Andrzej Szuba  1
Affiliations

Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study

Angelika Chachaj et al. PLoS One. .

Abstract

The study was designed to determine the associations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginines plasma concentrations with all-cause mortality in patients with hematological malignancies. 33 patients with acute myeloid leukemia (AML), 31 patients with non-Hodgkin's lymphoma (nHL), 32 patients with chronic lymphocytic leukemia (CLL) and 48 patients without malignancy were enrolled into the study. Each patient was followed until death or for at least 14.5 months (range: 14.5-53). Median ADMA and SDMA were significantly elevated in AML, nHL and CLL compared to controls (ADMA: 1.36, 1.24, 1.03, 0.55 μmol/l respectively, p<0.0001; SDMA: 0.86, 0.76, 0.71, 0.52 μmol/l respectively, p<0.0001). High ADMA and SDMA were associated with increased risk for all-cause mortality in CLL group (Hazard ratio (HR) for ADMA: 3.05, 95% CI:1.58-5.88, p = 0.001; HR for SDMA: 4.71, 95% CI:1.91-11.58, p = 0.001). Our study suggests that ADMA and SDMA could be novel prognostic factors for all-cause mortality in CLL patients.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Kaplan–Meier survival curve analysis in relation to ADMA and SDMA in hematological groups.
p was calculated using Cox regression analysis.
See this image and copyright information in PMC

References

    1. Boger RH. Asymmetric dimethylarginine: understanding the physiology, genetics, and clinical relevance of this novel biomarker. Proceedings of the 4th International Symposium on ADMA. Pharmacol Res. 2009;60:447. - PubMed
    1. Boger RH, Vallance P, Cooke JP. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atheroscler Suppl. 2003. December;4(4):1–3. - PubMed
    1. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide. 1997. February;1(1):65–73. doi: 10.1006/niox.1996.0106 - DOI - PubMed
    1. Schwedhelm E, Boger RH. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol. 2011. May;7(5):275–85. doi: 10.1038/nrneph.2011.31 - DOI - PubMed
    1. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 1997. December;52(6):1593–601. - PubMed

Publication types

MeSH terms